New review article on mHSPC and mCRPC

Below you will find a link to a valuable new review article on ongoing changes in the opportunities for evaluation and management of men with both hormone-sensitive and castration-resistant, metastatic prostate cancer (mHSPC and mCRPC). … READ MORE …

Does Test X change what physicians actually do and say to their patients?

One of the key ways in which we can (and do) assess the “value” of new types of medical test is by the degree to which they actually change the ways physicians act on the data and make decisions and/or recommendations about patient management. … READ MORE …

Race and decision-making in prostate cancer management

An article in Oncology Nurse Advisor notes that “Black and white men prioritize certain treatment-related factors differently when considering prostate cancer treatment options.” … READ MORE …

Why do African Americans do better on Provenge than whites?

In general, being of African American race is not a good thing when it comes to prostate cancer-related risk (for getting diagnosed with the disease or for outcomes over time). However, … … READ MORE …

Targeted photodynamic therapy for challenging forms of prostate cancer

We already know that linking certain types of radioactive agent to specific forms of prostate-specific membrane antigen (PSMA) offers new opportunities for the treatment of challenging cases of prostate cancer. … READ MORE …

Should you be adding abiraterone acetate to your ADT?

The data previously reported from the STAMPEDE trial and the LATITUDE trial over the past couple of days were from men newly diagnosed with high-risk and/or metastatic forms of prostate cancer, but … READ MORE …

Brachy boost therapy should be reserved for unfavorable risk patients

The ASCENDE-RT trial showed that oncological outcomes were improved among both intermediate-risk and high-risk men who were treated with external beam radiation (EBRT) and a brachytherapy boost (LDR-BT) to the prostate and adjuvant androgen deprivation therapy (ADT) (see this link). … READ MORE …